Volibris is a medicine that is used alone or combined with other medicines to treat adults with pulmonary arterial hypertension (PAH). PAH is abnormally high blood pressure in the arteries of the lungs. Volibris is used in patients with class II or III disease. The ‘class’ reflects the seriousness of the disease: ‘class II’ involves slight limitation of physical activity and ‘class III’ involves marked limitation of physical activity. Volibris has been shown to be effective in PAH with no identified cause and in PAH caused by connective tissue disease. Volibris contains the active substance ambrisentan.
Therapeutic Indication
### Therapeutic indication Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease. Volibris is indicated for treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
C02KX02
ATC Item
ambrisentan
Pharmacotherapeutic Group
Antihypertensives
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ambrisentan | N/A | 安贝生坦 |
EMA Name
Volibris
Medicine Name
Volibris
Aliases
N/A
